Clinical Trials Logo

Vascular Diseases clinical trials

View clinical trials related to Vascular Diseases.

Filter by:

NCT ID: NCT05710653 Completed - Clinical trials for Endothelial Dysfunction

Inter-individual Physiological Response to a Training and Detraining Period in Cardiometabolic Risk Factors Subjects

VASCU-HEALTH
Start date: June 28, 2022
Phase: N/A
Study type: Interventional

Background: Although exercise training is a well described therapy for some cardiometabolic diseases such as obesity, type 2 diabetes, arterial hypertension, and metabolic syndrome, there is scarcity of knowledge about the post-exercise period term as 'detraining' where usually all physiological adaptations as cardiovascular and metabolic benefits are lost due to physical inactivity. Likewise, as some exercise training modalities as high-intensity interval training improve vascular parameters including endothelial dysfunction parameters as flow-mediated dilation (FMD%), and carotid-intima media thickness (c-IMT) during the 'training' period, there is little knowledge about how many 'volume' or 'intensity' of exercise training or physical activity per week is needed to maintain the exercise training benefits in populations with cardiometabolic risk factors such as those patients with arterial hypertension. This information will be of great interest for both improving and maintaining the vascular profile and health of Chilean adults with risk factors and to maintain a better vascular profile. Objective: To study the beneficial adaptations from the 'training' and 'detraining' period of exercise training on functional and structural vascular parameters in healthy and cardiometabolic risk factors adult subjects to improve the health profile. Methods: The investigators will conduct an experimental design of 5 groups of exercise training in healthy (controls) and hypertensive (HTN) patients (≥140 mmHg), with overweight/or obesity, men and women, with BMI ≥25 and ≤35 kg/m2, aged ≥18y, physically inactive (<150 min/week of low/moderate PA/week, or <75 min/week of vigorous PA) in the last 6 months will be invited for participating. The groups will be as follows; Group (HTNex will be compared with Group HTNcg). Group (ELEex will be compared with Group ELEcg). Group (NTex will be compared with Group NTcg). Each group will be compared in their physiological vascular adaptations before and after exercise training such as HIIT, and after 3 months of a detraining period. Results (hypothesis): The investigators hypothesized that the maintenance of vascular outcomes after the 'detraining' period is intensity-dependent in adults with HTN that participated of an exercise intervention.

NCT ID: NCT05704725 Completed - Clinical trials for Chorioretinal Vascular Disease

A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)

Start date: January 23, 2023
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to is to assess the ability of retina specialists to successfully administer, via an intravitreal (IVT) injection, a 2 mg dose of ABP 938, using the ABP 938 aflibercept prefilled syringe (PFS), compared to a 2 mg dose of aflibercept using the aflibercept PFS.

NCT ID: NCT05702996 Not yet recruiting - Clinical trials for Thrombotic Microangiopathies

Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies

GEMECULI
Start date: March 2023
Phase: Phase 3
Study type: Interventional

The main objective of this prospective multisite trial is to study the evolution of TMA (thrombotic microangiopathy) induced by gemcitabin and treated by eculizumab.

NCT ID: NCT05699200 Recruiting - Healthy Clinical Trials

A Study to Analyze the Role of Sympathetic Nervous System in Spontaneous Coronary Artery Dissection

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this research is to compare sympathetic function (flight or fight system) and arterial health including structure and mechanics of participants with history of spontaneous coronary artery dissection (SCAD) to age and sex matched control participants.

NCT ID: NCT05683093 Recruiting - Hypertension Clinical Trials

Cardiovascular Longitudinal ALSPAC Research Investigations Following Hypertensive Pregnancy in Young Adulthood

CLARITY
Start date: November 17, 2022
Phase:
Study type: Observational

The purpose of this study is to understand more about why young people who were born to a hypertensive pregnancy may have increased risk of high blood pressure and are often at increased risk of heart and blood vessel disease later in life.

NCT ID: NCT05666804 Recruiting - Clinical trials for Macular Polypoidal Choroidal Vasculopathy (PCV)

Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy

PROUD
Start date: February 6, 2023
Phase: Phase 3
Study type: Interventional

This study is a 60-week, two-arm, randomized, open-label, active-controlled, multi-center study in patients with Polypoidal choroidal vasculopathy (PCV) who have not previously received anti-Vascular endothelial growth factor (VEGF) treatment.

NCT ID: NCT05662943 Completed - Clinical trials for Age-Related Macular Degeneration

Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

Start date: December 5, 2022
Phase:
Study type: Observational

The purpose of the present study was to evaluate the outcomes of type 1 macular neovascularization (MNV), including polypoidal choroidal vasculopathy in patients treated tolerating subretinal fluid (SRF) using Aflibercept in a clinical setting. Approximately 150 patients are anticipated to be enrolled in this study. SRF is a primary type of fluid compartment prevalent in type 1 aneurysmal MNV. In a recent study, the prevalence of SRF during 24-month follow-up period was 36.7% to 38.8% in type 1 MNV and polypoidal choroidal vasculopathy (PCV), 20.0% in type 2 MNV, and 7.7% in type 3 MNV. In addition, patients with SRF showed better visual prognosis in type 1 MNV/PCV. For this reason, type 1 MNV is an appropriate candidate for evaluating the influence of tolerating SRF.

NCT ID: NCT05662787 Active, not recruiting - Clinical trials for Peripheral Arterial Disease

BOLT Lithotripsy RESTORE ATK Trial

RESTORE ATK
Start date: January 19, 2023
Phase: N/A
Study type: Interventional

The RESTORE (ATK) above the knee study is a prospective, non- randomized, multi-center study for treatment of stenotic lesions with the Bolt Intravascular Lithotripsy System.

NCT ID: NCT05659641 Enrolling by invitation - Clinical trials for Cardiovascular Diseases

The Branch-based Intraoperative Stent System in the Treatment of Stanford A Aortic Dissection(BROAD)

BROAD
Start date: January 18, 2023
Phase: N/A
Study type: Interventional

The purpose of the study was to evaluate the safety and efficacy of a branched type intraoperative stent system for the treatment of Stanford type A aortic dissection

NCT ID: NCT05655936 Recruiting - Obesity Clinical Trials

Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial

HHD
Start date: June 29, 2023
Phase: N/A
Study type: Interventional

This is a single site, single-blinded parallel randomized control trial that investigates a multi-level intervention to improve postpartum blood pressure in women with hypertensive disorder pregnancy. The investigators will recruit women diagnosed with a hypertensive disorder of pregnancy, identified between 3rd trimester and 2 weeks post-delivery. The investigators will randomize participants to receive usual care home blood pressure monitoring for 6 weeks versus an intervention of usual care + blood pressure and weight monitoring + a doula trained in heart health. This trial will be conducted in partnership with a local community-based organization, Healthy Start Inc.